
- /
- Supported exchanges
- / F
Ardelyx Inc (41X F) stock market data APIs
Ardelyx Inc Financial Data Overview
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get Ardelyx Inc data using free add-ons & libraries
Get Ardelyx Inc Fundamental Data
Ardelyx Inc Fundamental data includes:
- Net Revenue: 252 M
- EBITDA: -62 151 000
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: 2021-08-13
- EPS/Forecast: -0.36
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Ardelyx Inc News

Ardelyx to Report Full Year and Fourth Quarter 2024 Financial Results on February 20, 2025
Ardelyx, Inc. Conference call scheduled for 8:00 a.m. Eastern Time WALTHAM, Mass., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission ...


High Growth Tech Stocks To Watch In January 2025
In the last week, the United States market has stayed flat, yet it is up 24% over the past year with earnings forecasted to grow by 15% annually. In this context of robust growth and steady performanc...

Chairman David Mott Bets $1M on Ardelyx--Is This Biotech Stock Set to Skyrocket?
Ardelyx (NASDAQ:ARDX) just got a confidence boost from insider buying. Chairman David Mott scooped up 199,000 shares at an average price of $4.99, putting nearly $1 million on the line. The stock is h...

Ardelyx (ARDX) Moves 16.0% Higher: Will This Strength Last?
Ardelyx (ARDX) shares soared 16% in the last trading session to close at $5.88. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the s...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.